Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th.

Trevena Stock Up 7.3 %

Shares of TRVN stock opened at $1.80 on Thursday. Trevena has a 12-month low of $1.13 and a 12-month high of $19.23. The firm has a market capitalization of $1.55 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. The firm has a fifty day moving average of $2.14 and a 200-day moving average of $4.81.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million for the quarter. Research analysts expect that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.